Mapa stránek
- Aktuality
- Ipsen’s Half-year 2010 Results
- 21th Neuronal Plasticity Prize awarded to three eminent scientists for their research into the domain of the Neuroendocrine Control of Behavior: Thomas R. Insel, Bruce McEwen and Donald Pfaff
- Ipsen’s partner Roche confirms the promising efficacy profile of Taspoglutide
- Encouraging results of GuidAge®, large scale European trial conducted in the prevention of Alzheimer’s Dementia
- Ipsen’s partner Roche announces amendment of the trial protocols for the taspoglutide phase III programme
- OBI-1 developed by Ipsen and Inspiration has obtained a positive opinion for the orphan drug status in Europe
- Implementation of a Sponsored Level I American Depositary Receipt (ADR) program: A new step in Ipsen's development in the United States
- Combined Shareholders’ Meeting of Ipsen S.A. held on 28 May 2010
- “Epigenetic Dynamics in the Immune System”
- Launch of Ipsen’s Decapeptyl 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
- Ipsen’s fourth quarter and full year 2009 sales
- Ipsen and Inspiration Biopharmaceuticals enter into partnership to create a world leading hemophilia franchise
- “Sensory Systems: smell, taste, touch, hearing and vision”
- Ipsen’s Decapeptyl® 6-month formulation receives marketing authorization in France for the treatment of locally advanced or metastatic prostate cancer
- Ipsen announces the launch of Dysport® (abobotulinumtoxinA) in the United States for the treatment of cervical dystonia
- Ipsen’s first nine months of 2009 sales and update of Group financial objectives
- Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoint in the first phase III clinical trial
- Ipsen and Debiopharm conclude an exclusive worldwide license agreement for the development and commercialisation of the Ipsen’s proprietary CDC-25 inhibitor (IRC-083864 or Debio 0931), an anti-cancer agent. Debio 0931 has the potential to target major h
- Ipsen’s half year 2009 results
- Results of Phase I and Phase IIa clinical studies confirm the inhibitory effect of proprietary Ipsen’s BIM23A760 first-in-class “chimeric” compound on growth hormone, IGF-1 and prolactin levels
- Přípravek Smecta - zrušení částečné úhrady přípravku Smecta.
- Ipsen and PHARNEXT conclude an exclusive research, development and marketing agreement
- 20th Neuronal Plasticity Prize awarded to three eminent scientists for their research into the domain of the brain-machine interaction: Alim-Louis Benabid, Apostolos P. Georgopoulos and Miguel A. L. Nicolelis
- Ipsen’s first quarter 2009 sales and financial outlook for the full year
- Colloque Médecine et Recherche of La Fondation Ipsen: “Diabetes, Insulin and Alzheimer’s Disease”
- Ipsen’s full year 2008 results
- Ipsen’s full year 2008 sales
- Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge® in France
- "Creating the future: New challenges in biology and medicine”: Ipsen gathers a panel of world-renowned scientists
- Ipsen provides update on R&D pipeline and business opportunities at its Investor Day
- FDA’s first-cycle review of Reloxin® extended
- Ipsen announces its corporate agenda for 2009
- Setkání s distributory
- Hledat
- Mapa stránek
- posledni3
- Aktuality
- Ipsen’s Half-year 2010 Results
- 21th Neuronal Plasticity Prize awarded to three eminent scientists for their research into the domain of the Neuroendocrine Control of Behavior: Thomas R. Insel, Bruce McEwen and Donald Pfaff
- Ipsen’s partner Roche confirms the promising efficacy profile of Taspoglutide
- Encouraging results of GuidAge®, large scale European trial conducted in the prevention of Alzheimer’s Dementia
- Ipsen’s partner Roche announces amendment of the trial protocols for the taspoglutide phase III programme
- OBI-1 developed by Ipsen and Inspiration has obtained a positive opinion for the orphan drug status in Europe
- Implementation of a Sponsored Level I American Depositary Receipt (ADR) program: A new step in Ipsen's development in the United States
- Combined Shareholders’ Meeting of Ipsen S.A. held on 28 May 2010
- “Epigenetic Dynamics in the Immune System”
- Launch of Ipsen’s Decapeptyl 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
- Ipsen’s fourth quarter and full year 2009 sales
- Ipsen and Inspiration Biopharmaceuticals enter into partnership to create a world leading hemophilia franchise
- “Sensory Systems: smell, taste, touch, hearing and vision”
- Ipsen’s Decapeptyl® 6-month formulation receives marketing authorization in France for the treatment of locally advanced or metastatic prostate cancer
- Ipsen announces the launch of Dysport® (abobotulinumtoxinA) in the United States for the treatment of cervical dystonia
- Ipsen’s first nine months of 2009 sales and update of Group financial objectives
- Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoint in the first phase III clinical trial
- Ipsen and Debiopharm conclude an exclusive worldwide license agreement for the development and commercialisation of the Ipsen’s proprietary CDC-25 inhibitor (IRC-083864 or Debio 0931), an anti-cancer agent. Debio 0931 has the potential to target major h
- Ipsen’s half year 2009 results
- Results of Phase I and Phase IIa clinical studies confirm the inhibitory effect of proprietary Ipsen’s BIM23A760 first-in-class “chimeric” compound on growth hormone, IGF-1 and prolactin levels
- Přípravek Smecta - zrušení částečné úhrady přípravku Smecta.
- Ipsen and PHARNEXT conclude an exclusive research, development and marketing agreement
- 20th Neuronal Plasticity Prize awarded to three eminent scientists for their research into the domain of the brain-machine interaction: Alim-Louis Benabid, Apostolos P. Georgopoulos and Miguel A. L. Nicolelis
- Ipsen’s first quarter 2009 sales and financial outlook for the full year
- Colloque Médecine et Recherche of La Fondation Ipsen: “Diabetes, Insulin and Alzheimer’s Disease”
- Ipsen’s full year 2008 results
- Ipsen’s full year 2008 sales
- Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge® in France
- "Creating the future: New challenges in biology and medicine”: Ipsen gathers a panel of world-renowned scientists
- Ipsen provides update on R&D pipeline and business opportunities at its Investor Day
- FDA’s first-cycle review of Reloxin® extended
- Ipsen announces its corporate agenda for 2009
- e-shop
- Sponzoring
|
